Navigation Links
PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million
Date:12/1/2009

INCLINE VILLAGE, Nev., Dec. 1 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced revenue guidance for the fourth quarter ended December 31, 2009 of approximately $57 million, as compared with $69 million for the fourth quarter of 2008. Included in fourth quarter 2008 results was the first of two installment payments of $12.5 million from Alexion. Also included in fourth quarter 2008 results was a one-time $1.8 million payment from Genentech for the exercise of options to four additional antigens and extension of the option period for two antigens under its license agreement with PDL.

Royalty revenues are based on third quarter product sales by PDL's licensees and include $3.2 million for Synagis®, which is marketed by MedImmune. When compared with 2008, underlying product sales of Avastin® and Lucentis®, for which the average royalty rate paid in the fourth quarter was 1%, increased by greater than 25% and sales of Tysabri®, for which the underlying royalty rate is 3%, increased by 23%. Underlying product sales of Synagis®, for which the average royalty rate was 3%, decreased by more than 25%. Royalties from sales of Herceptin® decreased 8% despite an 8% increase in underlying Herceptin sales because of a change in the sales mix of ex-US manufactured Herceptin for which the Company receives a flat 3% royalty rate and US manufactured Herceptin for which the fourth quarter effective rate received from Genentech/Roche for US manufactured products was 1%.

The above guidance is preliminary and actual published results may differ from such guidance. PDL plans to release its financial results for the fourth quarter 2009 in late February 2010 and will hold a conference call to discuss financial results and provide an update on company activities. Additional infor
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
2. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
3. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
4. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
5. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
6. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
7. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
8. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
9. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
10. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
11. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... CA (PRWEB) January 15, 2014 ... research solutions, today announced that Lupin Limited, one of ... Freeslate’s CM Protégé PharmD System for high ... Mumbai, India, is focused on a wide range of ...
(Date:1/14/2014)... Carahsoft and CDS Federal Services have scheduled a ... EST (11am PST), “Natural Language Processing: Converting Raw Data ... can turn raw, heterogeneous data into actionable knowledge to ... webinar will last approximately one hour. , Synopsis: Big ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, has ... an emerging biomedical company acquiring, developing, manufacturing, and marketing ... Free report download: http://equitiesiq.com/reports/alliqua/ , In late ... and Board, which launched the company’s new strategy to ...
(Date:1/14/2014)... Toronto, Canada (PRWEB) January 14, 2014 ... and its motives and methods in product development and ... of the industry. This mistrust, fueled by concerns about ... further fed by reports of spectacular fines to the ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... Labs, Inc. (OTC Bulletin Board: GOVX ), a ... today announced the results of its Annual Shareholders Meeting, held ... re-elected seven nominees for directors of the company to serve ... successors are duly elected or appointed and qualified. They are: ...
... Inc., (OTC Bulletin Board: BHRT ) announces ... stem cell therapy on the first two congestive heart ... Tijuana through its Center of Excellence, Regenerative Medicine Institute ... agreement to establish a Center of Excellence for the ...
... 26 Verenium Corporation (Nasdaq: VRNM ... of high-performance industrial enzyme solutions, today announced the ... Vice President of Manufacturing. Bracken will report to ... Verenium,s Enzymes Business. "Kevin brings over ...
Cached Biology Technology:GeoVax Labs Inc. Announces Results of 2010 Annual Stockholders Meeting 2GeoVax Labs Inc. Announces Results of 2010 Annual Stockholders Meeting 3GeoVax Labs Inc. Announces Results of 2010 Annual Stockholders Meeting 4Bioheart Reports Significant Improvements in Heart Failure Patients from Center of Excellence Program 2Bioheart Reports Significant Improvements in Heart Failure Patients from Center of Excellence Program 3Bioheart Reports Significant Improvements in Heart Failure Patients from Center of Excellence Program 4Verenium Appoints Kevin Bracken Vice President of Manufacturing 2Verenium Appoints Kevin Bracken Vice President of Manufacturing 3
(Date:4/24/2014)... they often inject harmful proteins into the host ... However, in some plants, bacteria attack once they,ve ... Now, researchers at the University of Missouri have ... bacteriaknown mostly for attacking tomatoesto invade its host. ... that work with food-producing plants to enhance resistance ...
(Date:4/24/2014)... Rochelle, NY, April 24, 2014GEN Publishing recently introduced ... digital publication focusing on the application of OMICs ... as next-gen sequencing, are beginning to transform medical ... research over the past decade-and-a-half. , "GEN,s editors ... of pharmacogenomics, genomics, metabolomics, transcriptomics, etc. etc. for ...
(Date:4/24/2014)... New Rochelle, NY, April 24, 2014D-ribose is a ... nutritional supplement, and as a starting compound for ... of Escherichia coli to increase the ... step toward achieving more efficient industrial-scale production of ... in Industrial Biotechnology , a peer-reviewed journal ...
Breaking Biology News(10 mins):Plants send out signals attracting harmful bacteria, MU study finds 2
... LUMPUR, Malaysia, Oct. 17, 2012 Rising crime ... governments to increase monitoring and introduce reliable border ... aimed at criminal identification and automated immigration at ... drive biometrics adoption in the government vertical across ...
... 2012  Aware, Inc. (NASDAQ: AWRE ), a ... products, today reported financial results for its third quarter ... DSL service assurance hardware business have been reported as ... shutdown of that business during the third quarter. Accordingly, ...
... Adm. Matthew Klunder, the chief of naval research, told a ... and technology (S&T) conference this week that he intends to ... together on a quarterly basis, starting in 2013, to accelerate ... every two years, which is phenomenal and very valuableand probably ...
Cached Biology News:Increased Focus on Security Bolsters Growth of Biometrics Market in Asia-Pacific, Finds Frost & Sullivan 2Increased Focus on Security Bolsters Growth of Biometrics Market in Asia-Pacific, Finds Frost & Sullivan 3Increased Focus on Security Bolsters Growth of Biometrics Market in Asia-Pacific, Finds Frost & Sullivan 4Aware, Inc. Reports Third Quarter 2012 Financial Results 2Aware, Inc. Reports Third Quarter 2012 Financial Results 3Aware, Inc. Reports Third Quarter 2012 Financial Results 4Aware, Inc. Reports Third Quarter 2012 Financial Results 5Aware, Inc. Reports Third Quarter 2012 Financial Results 6In an uncertain world, Navy needs science and technology collaboration, chief says 2
... Mouse C2C12 cells were cultured in DMEM and ... In order to keep the antigens in their ... The cells are arrayed on a 12-well (5 ... specifically treated to enhance cellular attachment and to ...
... Sample Buffer is a convenient, ... experimental samples and Perfect RNA ... needs no dilution and is ... gels. Simply mix equal volumes ...
... cells were cultured in DMEM and harvested at ... to keep the antigens in their native forms, ... are arrayed on a 12-well (5 mm) adhesive ... to enhance cellular attachment and to minimize background ...
... CopyControl™ vector can be induced prior to ... provide the stability of single-copy BACs with ... other cloning vectors. The kits provide the ... insert size screening system) necessary to create ...
Biology Products: